Graves' disease following administration of second dose of SARS-CoV-2 vaccine

The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as p...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2021-12, Vol.14 (12), p.e246432
Main Authors: Goblirsch, Timothy James, Paulson, Ambika E, Tashko, Gerti, Mekonnen, Asefa Jejaw
Format: Article
Language:English
Subjects:
Adult
Antibodies
Antigens
BNT162 Vaccine
Breast cancer
Cardiac arrhythmia
Case Report
Case reports
Coronaviruses
COVID-19
COVID-19 Vaccines
Female
Graves Disease - drug therapy
Hemoglobin
Humans
Hyperthyroidism
Immunoglobulins
Metabolism
mRNA vaccines
Neutrophils
Patients
Remission (Medicine)
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thyroid gland
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves' disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves' disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2021-246432